– New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from the Oxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month – Exploratory Trial on the Impact of Investigational Combination AD113 on OSA Severity and Blood Pressure in...
CAMBRIDGE, Mass. August 30, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
CAMBRIDGE, Mass. August 28, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
Thursday, September 28, 9:10-9:40am presentation plus scheduling 1:1 meetings A live webcast may be accessed. News 2020 2021 2022 2023 Events Insights Past...
